FDA advisory panel rejects J&J drug for acute coronary syndrome
(Reuters) - Johnson & Johnson's anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.
The panel voted 10 to 0, with one abstention, against approval, saying data from a single clinical trial was not strong enough to justify approval, especially since some data from the trial was missing.
Xarelto is already used to treat and prevent deep vein thrombosis and pulmonary embolisms and to reduce the risk of stroke and blood clots in patients with an irregular heart beat that is not caused by heart problems.
- Abbas-led Palestinian body backs Hamas truce demands in Gaza |
- UPDATE 4-Train carrying MH17 bodies reaches government-held Ukrainian city
- Rebels likely downed Malaysian jet 'by mistake': U.S. officials
- Islamic State crushes and coerces on march towards Baghdad
- Microsoft sees end to Nokia losses, shares rise after hours
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video